Company intelligence / Profile preview

Galen US

Craigavon, Northern Ireland

Ownership: Private
Development stage: Other

Overview

Galen is a commercial-stage pharmaceutical company with established products across multiple therapeutic areas. The company expanded its portfolio through the acquisition of POA Pharma in January 2020, gaining access to rare metabolic disease products and expanding into Nordic markets.

Therapeutic areas: Women's HealthNeurologyRare DiseasesGastroenterologyMetabolic DisordersPsychiatryMen's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

POA Pharma (acquired)

Beyond the preview

Go deeper on Galen US.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galen US.

Explore the full profile